iCAD

iCAD, Inc. is a medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment is composed of radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

iCAD implements strategic changes to drive profitability and growth

iCAD is strategically focusing on cost reduction, revenue diversification, and transitioning to a subscription model to drive profitability by 2024. Leveraging partnerships with Google and other organizations, the company aims to expand its market reach and enhance operational efficiency. Despite facing competition and market challenges, iCAD remains optimistic about its growth prospects.

iCAD reports Q1 revenue decline, eyes growth in AI healthcare

iCAD faced revenue decline in Q1 2023, with a focus on detection and therapy segments, while maintaining a strong gross profit margin.
The company's Xoft technology and partnership with Google Health present promising growth opportunities in the AI healthcare space.
Challenges include lower-than-expected Xoft business revenue, competition in AI software, and delays in partnership agreements.

iCAD reports Q2 revenue decline, eyes growth through strategic partnerships

iCAD's Q2 2023 Earnings Call showcased a revenue decline but highlighted progress in the detection segment and strategic partnerships. The company aims for recurring revenue through subscription deals and is focused on cost reductions and stability. Opportunities lie in expanding partnerships and securing growth with healthcare facilities globally.

iCAD reports improved operational metrics and strategic partnerships in Q3 '23

iCAD's Q3 '23 earnings call highlighted operational improvements, strategic partnerships, and a focus on growth initiatives. Despite a revenue decline and operating loss, the company has made progress in reducing EBITDA loss and cash burn. iCAD's financial position remains stable with sufficient resources for planned operations.

iCAD reports improved financials and strategic growth initiatives for 2024

iCAD's financial performance showed improvements in revenue, EBITDA loss, and operational efficiency, driven by strategic initiatives.
The company's focus on AI solutions, geographic expansion, and recurring revenue model positions it for future growth.
While facing challenges in market adoption and OpEx increases, iCAD has opportunities to capitalize on market growth and new product developments.

iCAD reports revenue growth and strategic expansion in Q1 2024

iCAD's Q1 2024 performance reflects positive momentum with revenue growth, improved profitability metrics, and strategic advancements
The company's focus on innovation, market expansion, and cost control positions them well for future growth and market leadership
While challenges like revenue seasonality and competitive pressures exist, iCAD's strengths in product development and global expansion offer opportunities for sustained growth
Overall, iCAD's Q1 2024 earnings call underscores a promising outlook with a strong foundation for continued success in the medical technology sector

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iCAD, Inc. is a global medical technology company, which engages in the provision of cancer detection and therapy solutions. It operates through the Cancer Detection and Cancer Therapy segments. The Cancer Detection segment includes image analysis and workflow products. The Cancer Therapy segment relates to radiation therapy products. The company was founded in 1984 and is headquartered in Nashua, NH.

Icad (ICAD) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.14 per share a year ago.

Icad (ICAD) Reports Q1 Loss, Tops Revenue Estimates

NASHUA, N.H., May 15, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today reported its financial and operating results for the three months ended March 31, 2023.

iCAD Reports Financial Results for First Quarter Ended March 31, 2023

Schrodinger 

AI will be transformative for many industries because the technology allows companies to both save a great deal of money and generate much more revenue. On the savings front, AI can cheaply do many human tasks.

3 Industries Set to Be Transformed by the AI Revolution

Exact Sciences

It's certainly not easy to find millionaire-maker stocks if you only have $50,000 or less to invest. In order to turn that amount of money into $1 million using a single stock, you'll need vision, a contrary nature, tenacity, and a great deal of patience.

The 3 Best Millionaire-Maker Stocks to Buy for April 2023

ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer ProFound AI Risk offered higher accuracy than Tyrer-Cuzick v8 for all women, regardless of menopausal status, breast density, and family history of breast cancer

ProFound AI Risk Outperforms Traditional, Widely-Accepted Breast Cancer Risk Models for Both Short-term and Long-term Risk Assessments

iCAD, Inc. (NASDAQ:ICAD ) Q4 2022 Earnings Conference Call March 29, 2023 4:30 PM ET Company Participants Dana Brown - President, Chief Executive Officer ​Dan Shea - Interim Chief Financial Officer Linnell Faber - Executive Assistant to Chief Executive Officer Conference Call Participants Per Ostlund - Craig Hallum Capital Group Marie Thibault - BTIG Yale Jen - Laidlaw & Company David Turkaly - JMP Securities Francois Brisebois - Oppenheimer Frank Takkinen - Lake Street Capital Market Operator Good day and welcome to the iCAD Inc. Fourth Quarter and Full Year 2022 Earnings Call. At this time all participants have been placed on a listen-only mode and we will open the floor for your questions and comments after the presentation.

iCAD, Inc. (ICAD) Q4 2022 Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of -9.09% and 0.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q4 Loss, Misses Revenue Estimates

Strategy focused on profitability by end of 2024, using current cash on hand

iCAD Reports Financial Results for Fourth Quarter ended December 31, 2022 and Year End

iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference iCAD showcases Breast AI Suite at National Consortium of Breast Centers (NCoBC) 32nd Annual Conference

iCAD's Breast AI Suite Empowers Customers to Lead the Way in Support of FDA's National Breast Density Reporting Standard

Broadcom

Eaton

Fortinet

Jabil

Pubmatic

Roku

For the last two years, tech stocks have been weighed down by the Steet's worries about elevated inflation and the Fed's rate hikes in response to high inflation. But in the coming months, inflation is widely expected to drop sharply.

7 Tantalizing Technology Stocks to Buy for Long-Term Growth

Company is exploring strategic options for its Therapy business line Company is exploring strategic options for its Therapy business line

iCAD Previews Fourth Quarter Financial Results, Full Report on March 28, 2023

Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023 Company's Breast AI Suite of deep-learning breast cancer detection, density assessment and risk evaluation tools showcased at ECR 2023

New Real-World Clinical Evidence Confirms ProFound AI Boosts Radiologists' Efficiency and Accuracy

Allegro MicroSystems

General Motors

Lithium Americas Corp

Magnite

Materion

Sunoco

Growth stocks are indisputably heating up on Wall Street. In a recent CNBC article, the financial news outlet suggested that “retail investors” are responsible for the surge.

7 Super Speculative Stocks That Could Make You Very Rich

Daniel Shea appointed as interim Chief Financial Officer

iCAD Announces CFO Transition and Hires New Senior Vice President, US Commercial Sales, AI

Bionano Genomics

GlaxoSmithKline

Madrigal Pharmaceuticals

Verona Pharma

vTv Therapeutics

Choosing the best drug stocks to buy can be dicey because drug stocks have disadvantages and advantages. On the negative side, you often have to wait many years for promising drugs to prove themselves in clinical trials.

7 Drug Stocks That Will Soar in 2023

Expedia

Plug Power

Shoals Technologies Group

Tesla

United Continental Hlds

Workday

On Dec. 5, U.S. stocks were dragged down in part by renewed bearishness on the part of Morgan Stanley (NYSE: MS ) analyst Mike Wilson. However, with the U.S. services sector, the job market, and consumer spending holding up quite well, it's  difficult for me to imagine how the profit collapse predicted by Wilson could materialize.

Our 7 Top Nasdaq Stock Picks for 2023

Solis Mammography's Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI Solis Mammography's Chief Medical Officer Chirag Parghi, MD, to share clinical experience and real-world case studies demonstrating clinical value of ProFound AI

iCAD features Solis Mammography in upcoming “ProFound Insights, ProFound Impact” webinar

Study affirms utility of ProFound AI's Case Scores in improving cancer detection

Positive New Research Presented at RSNA 2022 Reaffirms iCAD's Breast AI Suite Improves Radiologists' Performance and Breast Cancer Detection

NASHUA, N.H., Nov. 15, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that Stacey Stevens, Chief Executive Officer, will participate at the 13th Annual Craig-Hallum Alpha Select Conference on Thursday, November 17th. The conference will be held at the Sheraton New York Times Square in New York City.

iCAD to Participate in the 13th Annual Craig-Hallum Alpha Select Conference

iCAD, Inc. (NASDAQ:ICAD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Linnell Faber - Executive Assistant to Chief Executive Officer Stacey Stevens - President & Chief Executive Officer Steve Sarno - Chief Financial Officer Conference Call Participants Per Ostlund - Craig Hallum Capital Group Francois Brisebois - Oppenheimer Operator Good afternoon ladies and gentlemen and welcome to the iCAD Incorporated Third Quarter 2022 Earnings Call. At this time all participants have been placed on a Listen Only mode and the floor will be open for questions and comments after the presentation.

iCAD, Inc. (ICAD) Q3 2022 Earnings Call Transcript

Icad (ICAD) delivered earnings and revenue surprises of -7.14% and 26.35%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Icad (ICAD) Reports Q3 Loss, Lags Revenue Estimates

Company implements corporate strategic realignment

iCAD Reports Financial Results for Third Quarter Ended September 30, 2022

Strategic commercial agreement in development will leverage Radiology Partners' clinical expertise, ability to scale and leadership position to drive nationwide adoption of iCAD's Breast AI Suite Strategic commercial agreement in development will leverage Radiology Partners' clinical expertise, ability to scale and leadership position to drive nationwide adoption of iCAD's Breast AI Suite

iCAD to Join Forces with Radiology Partners, the Nation's Largest Radiology Practice

The ongoing market-wide sell-off has been ruthless against small-cap tickers, but the comprehensive selling has uncovered iCAD. The ticker is currently undervalued with an attractive risk-reward. ICAD has lost about 81% of its value over the past twelve months. I suspect we could see a "snapback" move in the near term.

iCAD: Another Great Candidate For My 'Bio Boom' Speculative Portfolio

NASHUA, N.H., Oct. 27, 2022 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that it will release financial results for the third quarter ended September 30, 2022, after the market close, and host a conference call at 4:30 PM Eastern Time on November 10, 2022.

News for iCAD Stock (ICAD)